Multiplex CRISPR/Cas9 system impairs HCMV replication by excising an essential viral gene.
Anti-HCMV treatments used in immunosuppressed patients reduce viral replication, but resistant viral strains can emerge. Moreover, these drugs do not target latently infected cells. We designed two anti-viral CRISPR/Cas9 strategies to target the UL122/123 gene, a key regulator of lytic replication a...
Main Authors: | Janina Gergen, Flora Coulon, Alison Creneguy, Nathan Elain-Duret, Alejandra Gutierrez, Olaf Pinkenburg, Els Verhoeyen, Ignacio Anegon, Tuan Huy Nguyen, Franck Albert Halary, Fabienne Haspot |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5813945?pdf=render |
Similar Items
-
The CRISPR/Cas9 system as an anti-viral strategy against the human cytomegalovirus
by: Gergen, Janina
Published: (2017) -
HCMV Infection and Apoptosis: How Do Monocytes Survive HCMV Infection?
by: Donna Collins-McMillen, et al.
Published: (2018-09-01) -
HCMV-infected cells maintain efficient nucleotide excision repair of the viral genome while abrogating repair of the host genome.
by: John M O'Dowd, et al.
Published: (2012-01-01) -
Association of human cytomegalovirus (HCMV) neutralizing antibodies with antibodies to the HCMV glycoprotein complexes
by: Miho Shibamura, et al.
Published: (2020-08-01) -
Dual agents against HIV and HCMV
by: Anastasia Khandazhinskaya, et al.
Published: (2018-05-01)